Paul J Maglione1, Huaibin M Ko2, Mary B Beasley3, James A Strauchen3, Charlotte Cunningham-Rundles4. 1. Immunology Institute, Mount Sinai School of Medicine, New York, NY; Department of Medicine, Mount Sinai School of Medicine, New York, NY. 2. Department of Pathology, Mount Sinai School of Medicine, New York, NY. 3. Department of Medicine, Mount Sinai School of Medicine, New York, NY; Department of Pathology, Mount Sinai School of Medicine, New York, NY. 4. Immunology Institute, Mount Sinai School of Medicine, New York, NY; Department of Medicine, Mount Sinai School of Medicine, New York, NY; Department of Pediatrics, Mount Sinai School of Medicine, New York, NY. Electronic address: Charlotte.Cunningham-Rundles@mssm.edu.
Abstract
BACKGROUND: Despite reducing pneumonia and other infections, antibody replacement does not appear to treat pulmonary lymphoid hyperplasia (PLH) in patients with common variable immunodeficiency (CVID). The pathogenesis and optimal treatments remain to be clarified. OBJECTIVE: We aimed to better understand the pathology of CVID-associated lung disease. Tertiary lymphoneogenesis, although a component of interstitial lung disease associated with autoimmune diseases, has not previously been explored in patients with CVID. METHODS: We examined the clinical characteristics and pathologic findings of 6 patients with CVID with nodular/infiltrative lung disease who had biopsy specimens demonstrating PLH. RESULTS: In these subjects regions of PLH contained distinct B- and T-cell zones, with B-cell predominance in 1 patient and T-cell predominance in the others. Colocalization of Ki67, Bcl6, and CD23 within this ectopic lymphoid architecture demonstrated tertiary lymphoneogenesis with active centers of cellular proliferation. One patient received rituximab with improved pulmonary radiologic findings. CONCLUSION: Ectopic lymphoid tissue forming germinal centers suggest tertiary lymphoneogenesis in CVID-associated lung disease. B cell-targeted therapy might disrupt CVID-associated lymphoid hyperplasia.
BACKGROUND: Despite reducing pneumonia and other infections, antibody replacement does not appear to treat pulmonary lymphoid hyperplasia (PLH) in patients with common variable immunodeficiency (CVID). The pathogenesis and optimal treatments remain to be clarified. OBJECTIVE: We aimed to better understand the pathology of CVID-associated lung disease. Tertiary lymphoneogenesis, although a component of interstitial lung disease associated with autoimmune diseases, has not previously been explored in patients with CVID. METHODS: We examined the clinical characteristics and pathologic findings of 6 patients with CVID with nodular/infiltrative lung disease who had biopsy specimens demonstrating PLH. RESULTS: In these subjects regions of PLH contained distinct B- and T-cell zones, with B-cell predominance in 1 patient and T-cell predominance in the others. Colocalization of Ki67, Bcl6, and CD23 within this ectopic lymphoid architecture demonstrated tertiary lymphoneogenesis with active centers of cellular proliferation. One patient received rituximab with improved pulmonary radiologic findings. CONCLUSION: Ectopic lymphoid tissue forming germinal centers suggest tertiary lymphoneogenesis in CVID-associated lung disease. B cell-targeted therapy might disrupt CVID-associated lymphoid hyperplasia.
Authors: Stina Salomonsson; Malin V Jonsson; Kathrine Skarstein; Karl A Brokstad; Peter Hjelmström; Marie Wahren-Herlenius; Roland Jonsson Journal: Arthritis Rheum Date: 2003-11
Authors: Javier de Gracia; Montserrat Vendrell; Antonio Alvarez; Esther Pallisa; Maria-José Rodrigo; David de la Rosa; Fernando Mata; Jordi Andreu; Ferran Morell Journal: Int Immunopharmacol Date: 2004-06 Impact factor: 4.932
Authors: Catharina M L Touw; Annick A van de Ven; Pim A de Jong; Suzanne Terheggen-Lagro; Erik Beek; Elisabeth A M Sanders; Joris M van Montfrans Journal: Pediatr Allergy Immunol Date: 2009-11-13 Impact factor: 6.377
Authors: Paul J Maglione; Gavin Gyimesi; Montserrat Cols; Lin Radigan; Huaibin M Ko; Tamar Weinberger; Brian H Lee; Emilie K Grasset; Adeeb H Rahman; Andrea Cerutti; Charlotte Cunningham-Rundles Journal: JCI Insight Date: 2019-03-07
Authors: Paul J Maglione; Jessica R Overbey; Lin Radigan; Emilia Bagiella; Charlotte Cunningham-Rundles Journal: Ann Allergy Asthma Immunol Date: 2014-05-29 Impact factor: 6.347